🌸 Breast Cancer — 2026-W42

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Randomized phase II/III trial in oligometastatic breast cancer on first-line systemic therapy, published in J Clin Oncol. Evaluates whether adding metastasis-directed ablation improves progression-free survival, informing the use of local ablative therapy in this setting.

Narrative state-of-the-art review of systemic breast cancer treatment across subtypes, published in NEJM. Summarizes recent advances in targeted therapy, antibody-drug conjugates, and immunotherapy to inform biomarker-guided treatment and sequencing.

Narrative review of HER2-positive breast cancer treatment algorithms across early and advanced disease, published in Nature Reviews Clinical Oncology. Discusses de-escalation, escalation and sequencing with trastuzumab deruxtecan and other HER2-targeted agents, highlighting evidence gaps to guide treatment tailoring.

Randomized controlled trial of frozen glove and sock cryotherapy to prevent taxane-induced neuropathy, published in Annals of Oncology. The primary endpoint was not met, though some patient-reported neuropathy symptoms improved, so cryotherapy is not established as a preventive standard.

Secondary analysis of a pragmatic cluster-randomized trial in breast cancer patients receiving first-line chemotherapy with prophylactic CSF, published in JCO Oncol Pract. Compares in-clinic, on-body device and self-injection delivery and suggests febrile neutropenia rates were similarly low across methods, supporting flexibility in delivery.

Retrospective National Cancer Database cohort in HR-positive/HER2-negative pN2-3 early breast cancer with low 21-gene recurrence scores, published in JNCI. Suggests adjuvant chemotherapy is associated with better survival in this group lacking prospective data, though confounding by selection limits conclusions.

Translational biomarker study in Clin Cancer Res measuring circulating endotrophin in breast cancer patients, linking levels to treatment response in the metastatic setting. Exploratory; it does not yet guide a specific therapy decision.

Real-world clinicogenomic database analysis in adults with advanced solid tumors, published in JCO Precision Oncology. Uses matched emulation to assess whether NTRK fusions affect survival independent of TRK inhibitor therapy, informing prognostic interpretation rather than treatment selection.

Retrospective SEER database analysis with propensity matching in early multifocal/multicentric breast cancer, published in JCO Precision Oncology. Suggests adjuvant chemotherapy benefit is limited in node-negative disease under 1 cm, informing chemotherapy decisions but with inherent retrospective limitations.

Retrospective model development and validation of a brain metastasis risk calculator in stage I-III breast cancer, published in JNCI. May support risk stratification and surveillance or trial selection, but does not guide a specific systemic therapy choice.